The hottest interpretation on the domestic pharmac

2022-07-27
  • Detail

Unscrambling the domestic pharmaceutical packaging market (Part 1)

pharmaceutical packaging, as a very active branch in China's packaging field, its continuous renewal and progress have witnessed the rapid development of the packaging industry. After China's entry into WTO, more and more international pharmaceutical enterprises began to enter China. On the one hand, this intensified the competition in China's pharmaceutical industry, on the other hand, it also improved the quality and technical level of the entire industry, which has become an inevitable trend to drive the development of pharmaceutical packaging. As the pharmaceutical industry is closely related to people's lives, it has created the particularity of pharmaceutical packaging. Therefore, in China, pharmaceutical packaging belongs to the category of national food and drug administration. However, from the technical point of view, the relationship between pharmaceutical packaging and packaging printing is very large, so it is reasonable to pay attention to pharmaceutical packaging! Based on this background, we interviewed Mr. chenqixiang, Secretary General of the packaging and Printing Committee of China Packaging Technology Association, and Mr. Jiwei, director of Shanghai pharmaceutical packaging testing institute, to jointly interpret the domestic pharmaceutical packaging market. Perspective on the current situation of pharmaceutical packaging according to director Ji, at present, China's pharmaceutical enterprises are mainly distributed in Jiangsu, Zhejiang and Guangdong. In terms of quantity and scale, the pharmaceutical enterprises in Guangdong and Jiangsu and Zhejiang occupy a leading position. From the development of the past two years, the large-scale production of pharmaceutical enterprises is becoming more and more obvious, and the grade is also gradually improving. A development trend of modern pharmaceutical enterprises is that larger pharmaceutical factories are equipped with packaging enterprises. At present, the extensive growth with high speed, low benefit and high consumption is a typical feature of the development of pharmaceutical packaging in China. The packaging quality of most domestic pharmaceutical products is low, and there is still a big gap with developed countries. This can be proved by the following two data. At present, 65% of China's pharmaceutical packaging products are not up to the level of the international developed countries in the 1980s, and the quality of packaging materials and the contribution rate of packaging to the pharmaceutical industry are low. In developed countries, pharmaceutical packaging accounts for 30% of the value of drugs, while the proportion in China is less than 10%. At present, for the large-scale domestic pharmaceutical packaging enterprises, there is little difference in equipment compared with foreign countries, but the software environment is not satisfactory. It is understood that the reasons for this gap are mainly concentrated in three aspects. First, the overall level of China's pharmaceutical industry is low, and the technology of pharmaceutical production enterprises is relatively backward. From the perspective of the scale of pharmaceutical enterprises, there are many small pharmaceutical enterprises in China, the repeated production of drugs is serious, and the management level of pharmaceutical enterprises is low. Secondly, the relevant regulations and technical standards of China's pharmaceutical packaging industry are backward. At present, China has gradually launched a standard system for the pharmaceutical industry, but there is still a certain distance from the international standards. The lack of industry standard system leads to the situation that the packaging of pharmaceutical products is neither good nor bad. Finally, there are drawbacks in the drug circulation system. Pharmaceutical products have been mainly sold in hospitals for a long time, and the drugs sold in pharmacies only account for a small part of the total. This situation restricts the direct participation of drugs in market competition and restricts the development of pharmaceutical packaging. In addition, the current drug bidding system has seriously dampened the enthusiasm of pharmaceutical manufacturers. Enterprises are unable to make great efforts to reform the packaging. Pharmaceutical packaging has remained old-fashioned for a long time. In addition, the backward technical level of pharmaceutical packaging machinery, equipment and materials and the weak quality awareness of employees are also factors restricting the development of pharmaceutical product packaging in China. The introduction of pharmaceutical packaging design standards is a broad concept, and packaging design is a link that is easy to be ignored. According to director Ji, two factors should be considered in the design of pharmaceutical packaging, one is safety, the other is national characteristics. Compared with developed countries, there is still a certain distance in China's pharmaceutical packaging design level. For example, the use of drug names and batch numbers is not standardized, the use and quality standards of drug labels are not consistent, the use of terms is not standardized, the drugs are over packaged, and there are no instructions. The design does not reflect national characteristics, and is not consistent with national culture and public aesthetic needs. Secretary General Chen believes that the pharmaceutical packaging design should also pay attention to humanization, simplicity, practicality and easy operation. However, a large part of the domestic pharmaceutical packaging design does not consider these links, which to some extent restrict the rapid development of the pharmaceutical packaging industry, This is also a practical problem that Changshu national high tech Zone must pay attention to and solve in order to avoid the two-way development of electrostatic induction, investment attraction and talent attraction. With the improvement of people's consumption level and the introduction of new regulations and standards in relevant industries, the pharmaceutical product packaging industry has undergone a fundamental change. At present, almost all the top 100 global pharmaceutical enterprises have established joint ventures or wholly-owned pharmaceutical enterprises in China, which not only brings more new drug varieties, but also advanced pharmaceutical packaging concepts and standards. In order to adapt to this change, China's "Drug Administration Law" has added a chapter of "drug packaging and sub packaging", which makes special provisions on the issue of pharmaceutical packaging. Including: the name, specification, manufacturer, approval number, product batch number, main ingredients, indications, usage, dosage, contraindications, adverse reactions and precautions of the drug must be indicated on the label or instruction manual of the drug package. The measures for the administration of materials and containers for pharmaceutical packaging (Provisional) (order 21) issued in 2000 and the provisions on the administration of pharmaceutical packaging, labels and instructions (order 23) also make detailed provisions on pharmaceutical packaging. According to Secretary General Chen, the regulations on the administration of pharmaceutical packaging, labels and instructions (Order No. 23) issued by the State Drug Administration not only standardized the standards of China's pharmaceutical packaging industry, but also unified the form of pharmaceutical packaging, which not only improved the requirements for hygiene and protection functions, but also emphasized the convenience and scientificity of use. In addition, the fierce market competition also puts forward higher requirements for the cost control of packaging. In the use of packaging materials, many composite materials have been widely used to strengthen the quality of packaging and improve the grade of drugs; The design of the outer packaging container and the anti-counterfeiting with the test report have also been paid attention to by pharmaceutical enterprises

Copyright © 2011 JIN SHI